Snus Market Share, Demand, Scope, Growth And Forecast 2024-2032

IMARC Group's report titled "Snus Market Report by Product Type (Loose Snus, Portion Snus), Flavors (Mint, Berries, Dry Fruit, and Others), Distribution Channel (Tobacco...
HomeHealth NewsInsomnia Market Report 2024, Growth, Size, Demand and Forecast 2032

Insomnia Market Report 2024, Growth, Size, Demand and Forecast 2032

I am vishalguptaimarc (vishalgupta.imarc@gmail.com). I hold full responsibility for this content, which includes text, images, links, and files. The website administrator and team cannot be held accountable for this content. If there is anything you need to discuss, you can reach out to me via vishalgupta.imarc@gmail.com email.

Disclaimer: The domain owner, admin and website staff of New York Times Now, had no role in the preparation of this post. New York Times Now, does not accept liability for any loss or damages caused by the use of any links, images, texts, files, or products, nor do we endorse any content posted in this website.

IMARC Group’s report titled “Insomnia Market Report by Therapy Type (Non-Pharmacological Therapy, Pharmacological Therapy), Drug Class (Antidepressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and Region 2024-2032“. offers a comprehensive analysis of the industry, which comprises insights on the global insomnia market report. The global market size reached US$ 5.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.6 Billion by 2032, exhibiting a growth rate (CAGR) of 2.69% during 2024-2032.

Grab a sample PDF of this report: https://www.imarcgroup.com/insomnia-market/requestsample

Factors Affecting the Growth of the Insomnia Industry:

  • Aging Population:

Insomnia is more common among older adults. As the global population is aging, there is a higher overall prevalence of sleep disorders, including insomnia, which leads to a greater demand for treatment and management solutions. Aging is associated with changes in sleep patterns and sleep architecture. Older individuals often experience difficulties falling asleep, staying asleep, and maintaining deep sleep, which can contribute to the development or exacerbation of insomnia. Elderly individuals are more likely to have comorbid medical conditions, such as chronic pain, arthritis, and mental health disorders, which can increase the risk of insomnia.

  • Technological Advancements:

Technological innovations are giving rise to wearable devices and smartphone applications that can track and monitor sleep patterns. These devices provide individuals with insights into their sleep quality and can detect issues like insomnia. As a result, more people are motivated to seek solutions for their sleep problems. Telemedicine and remote health monitoring technologies enable healthcare providers to assess and diagnose sleep disorders, including insomnia, without requiring in-person visits. This makes it easier for individuals to access medical advice and treatment recommendations.

  • Increasing Stress Levels:

High levels of stress can cause sleep disturbances, making it difficult for individuals to fall asleep or stay asleep throughout the night. This is leading to an increasing likelihood of developing insomnia. Prolonged exposure to chronic stress can result in persistent sleep problems. Individuals experiencing chronic stress are seeking medical help for their sleep issues, catalyzing the demand for insomnia treatments. Stress can cause anxiety and depression, both of which are risk factors for insomnia. The psychological toll of stress can lead individuals to seek therapy or medication to address their sleep difficulties.

Leading Companies Operating in the Global Insomnia Industry:

  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Biocodex
  • Eisai Co. Ltd.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co. Inc.
  • Neurim Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.)
  • Takeda Pharmaceutical Company Limited
  • Vanda Pharmaceuticals Inc.

Insomnia Market Report Segmentation:

By Therapy Type:

  • Non-Pharmacological Therapy
    • Hypnotherapy
    • Cognitive Behavioral Therapy
    • Medical Devices
    • Others
  • Pharmacological Therapy
    • Prescription Sleep Aids
    • Over-The-Counter Sleep Aids

Pharmacological therapy represents the largest segment as pharmaceutical medications are often the initial choice for treating insomnia, offering quick relief for individuals with sleep difficulties.

By Drug Class:

  • Antidepressants
  • Melatonin Antagonist
  • Benzodiazepines
  • Nonbenzodiazepines
  • Orexin Antagonist
  • Others

Benzodiazepines accounts for the majority of the market share due to their widespread use in insomnia treatment, as they are known for their sedative properties and ability to induce sleep in patients with sleep disorders.

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Based on the distribution channel, the market has been divided into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

Regional Insights:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

North America enjoys the leading position in the insomnia market on account of the high prevalence of sleep disorders, greater awareness, and access to healthcare services.

Global Insomnia Market Trends:

With growing concerns about the side effects and dependency associated with prescription sleep medications, there is a shift towards non-pharmacological interventions for managing insomnia. Cognitive-behavioral therapy for insomnia (CBT-I), relaxation techniques, and mindfulness-based therapies are gaining traction as effective alternatives.

Healthcare providers are recognizing the need for personalized treatment approaches in managing insomnia. Advancements in genetic testing and biomarker identification allow for tailored interventions based on the genetic predisposition of individuals, underlying health conditions, and lifestyle factors.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163